(HLN) Haleon - Overview
Exchange: NYSE •
Country: United Kingdom •
Currency: USD •
Type: Common Stock •
ISIN: US4055521003
Stock:
Total Rating 51
Risk 90
Buy Signal 0.54
| Risk 5d forecast | |
|---|---|
| Volatility | 31.8% |
| Relative Tail Risk | 0.25% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.25 |
| Alpha | 2.18 |
| Character TTM | |
|---|---|
| Beta | 0.127 |
| Beta Downside | -0.025 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.11% |
| CAGR/Max DD | 0.61 |
EPS (Earnings per Share)
Revenue
Description: HLN Haleon
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 2.41b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.57 > 1.0 |
| NWC/Revenue: -3.75% < 20% (prev -5.38%; Δ 1.64% < -1%) |
| CFO/TA 0.12 > 3% & CFO 3.94b > Net Income 2.41b |
| Net Debt (7.78b) to EBITDA (4.04b): 1.93 < 3 |
| Current Ratio: 0.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (4.53b) vs 12m ago -1.61% < -2% |
| Gross Margin: 63.19% > 18% (prev 0.61%; Δ 6258 % > 0.5%) |
| Asset Turnover: 50.71% > 50% (prev 50.83%; Δ -0.11% > 0%) |
| Interest Coverage Ratio: 7.63 > 6 (EBITDA TTM 4.04b / Interest Expense TTM 484.5m) |
Altman Z'' 4.48
| A: -0.02 (Total Current Assets 4.14b - Total Current Liabilities 4.76b) / Total Assets 31.83b |
| B: 0.86 (Retained Earnings 27.27b / Total Assets 31.83b) |
| C: 0.11 (EBIT TTM 3.70b / Avg Total Assets 32.61b) |
| D: 1.01 (Book Value of Equity 15.94b / Total Liabilities 15.83b) |
| Altman-Z'' Score: 4.48 = AA |
Beneish M -3.09
| DSRI: 1.03 (Receivables 2.14b/2.14b, Revenue 16.54b/16.98b) |
| GMI: 0.97 (GM 63.19% / 61.18%) |
| AQI: 1.01 (AQ_t 0.81 / AQ_t-1 0.80) |
| SGI: 0.97 (Revenue 16.54b / 16.98b) |
| TATA: -0.05 (NI 2.41b - CFO 3.94b) / TA 31.83b) |
| Beneish M-Score: -3.09 (Cap -4..+1) = AA |
What is the price of HLN shares?
As of February 27, 2026, the stock is trading at USD 10.76 with a total of 10,608,356 shares traded.
Over the past week, the price has changed by -3.15%, over one month by +3.76%, over three months by +10.25% and over the past year by +7.43%.
Over the past week, the price has changed by -3.15%, over one month by +3.76%, over three months by +10.25% and over the past year by +7.43%.
Is HLN a buy, sell or hold?
Haleon has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy HLN.
- StrongBuy: 2
- Buy: 2
- Hold: 0
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the HLN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.9 | 10.9% |
| Analysts Target Price | 11.9 | 10.9% |
HLN Fundamental Data Overview February 27, 2026
Market Cap GBP = 34.45b (46.49b USD * 0.7411 USD.GBP)
P/E Trailing = 23.2
P/E Forward = 16.5289
P/S = 4.2191
P/B = 1.8455
P/EG = 2.664
Revenue TTM = 16.54b GBP
EBIT TTM = 3.70b GBP
EBITDA TTM = 4.04b GBP
Long Term Debt = 7.58b GBP (from longTermDebt, last quarter)
Short Term Debt = 813.0m GBP (from shortTermDebt, last quarter)
Debt = 8.45b GBP (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.78b GBP (from netDebt column, last quarter)
Enterprise Value = 42.23b GBP (34.45b + Debt 8.45b - CCE 676.0m)
Interest Coverage Ratio = 7.63 (Ebit TTM 3.70b / Interest Expense TTM 484.5m)
EV/FCF = 28.18x (Enterprise Value 42.23b / FCF TTM 1.50b)
FCF Yield = 3.55% (FCF TTM 1.50b / Enterprise Value 42.23b)
FCF Margin = 9.06% (FCF TTM 1.50b / Revenue TTM 16.54b)
Net Margin = 14.57% (Net Income TTM 2.41b / Revenue TTM 16.54b)
Gross Margin = 63.19% ((Revenue TTM 16.54b - Cost of Revenue TTM 6.09b) / Revenue TTM)
Gross Margin QoQ = 64.51% (prev 64.51%)
Tobins Q-Ratio = 1.33 (Enterprise Value 42.23b / Total Assets 31.83b)
Interest Expense / Debt = 1.53% (Interest Expense 129.0m / Debt 8.45b)
Taxrate = 24.37% (262.0m / 1.07b)
NOPAT = 2.80b (EBIT 3.70b * (1 - 24.37%))
Current Ratio = 0.87 (Total Current Assets 4.14b / Total Current Liabilities 4.76b)
Debt / Equity = 0.53 (Debt 8.45b / totalStockholderEquity, last quarter 15.94b)
Debt / EBITDA = 1.93 (Net Debt 7.78b / EBITDA 4.04b)
Debt / FCF = 5.19 (Net Debt 7.78b / FCF TTM 1.50b)
Total Stockholder Equity = 16.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.39% (Net Income 2.41b / Total Assets 31.83b)
RoE = 14.89% (Net Income TTM 2.41b / Total Stockholder Equity 16.19b)
RoCE = 15.56% (EBIT 3.70b / Capital Employed (Equity 16.19b + L.T.Debt 7.58b))
RoIC = 11.09% (NOPAT 2.80b / Invested Capital 25.20b)
WACC = 5.35% (E(34.45b)/V(42.91b) * Re(6.38%) + D(8.45b)/V(42.91b) * Rd(1.53%) * (1-Tc(0.24)))
Discount Rate = 6.38% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.00%
[DCF] Terminal Value 84.92% ; FCFF base≈1.60b ; Y1≈1.41b ; Y5≈1.15b
[DCF] Fair Price = 6.07 (EV 34.79b - Net Debt 7.78b = Equity 27.02b / Shares 4.45b; r=5.90% [WACC]; 5y FCF grow -15.03% → 2.90% )
EPS Correlation: 8.23 | EPS CAGR: 104.2% | SUE: -0.01 | # QB: 0
Revenue Correlation: 56.46 | Revenue CAGR: 23.41% | SUE: 1.66 | # QB: 1
EPS current Year (2026-12-31): EPS=0.55 | Chg7d=+0.000 | Chg30d=+0.004 | Revisions Net=+2 | Growth EPS=+7.9% | Growth Revenue=+3.9%
EPS next Year (2027-12-31): EPS=0.60 | Chg7d=+0.000 | Chg30d=+0.005 | Revisions Net=+2 | Growth EPS=+9.2% | Growth Revenue=+5.0%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.6% (Discount Rate 7.9% - Earnings Yield 4.3%)
[Growth] Growth Spread = +1.4% (Analyst 5.0% - Implied 3.6%)
P/E Trailing = 23.2
P/E Forward = 16.5289
P/S = 4.2191
P/B = 1.8455
P/EG = 2.664
Revenue TTM = 16.54b GBP
EBIT TTM = 3.70b GBP
EBITDA TTM = 4.04b GBP
Long Term Debt = 7.58b GBP (from longTermDebt, last quarter)
Short Term Debt = 813.0m GBP (from shortTermDebt, last quarter)
Debt = 8.45b GBP (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.78b GBP (from netDebt column, last quarter)
Enterprise Value = 42.23b GBP (34.45b + Debt 8.45b - CCE 676.0m)
Interest Coverage Ratio = 7.63 (Ebit TTM 3.70b / Interest Expense TTM 484.5m)
EV/FCF = 28.18x (Enterprise Value 42.23b / FCF TTM 1.50b)
FCF Yield = 3.55% (FCF TTM 1.50b / Enterprise Value 42.23b)
FCF Margin = 9.06% (FCF TTM 1.50b / Revenue TTM 16.54b)
Net Margin = 14.57% (Net Income TTM 2.41b / Revenue TTM 16.54b)
Gross Margin = 63.19% ((Revenue TTM 16.54b - Cost of Revenue TTM 6.09b) / Revenue TTM)
Gross Margin QoQ = 64.51% (prev 64.51%)
Tobins Q-Ratio = 1.33 (Enterprise Value 42.23b / Total Assets 31.83b)
Interest Expense / Debt = 1.53% (Interest Expense 129.0m / Debt 8.45b)
Taxrate = 24.37% (262.0m / 1.07b)
NOPAT = 2.80b (EBIT 3.70b * (1 - 24.37%))
Current Ratio = 0.87 (Total Current Assets 4.14b / Total Current Liabilities 4.76b)
Debt / Equity = 0.53 (Debt 8.45b / totalStockholderEquity, last quarter 15.94b)
Debt / EBITDA = 1.93 (Net Debt 7.78b / EBITDA 4.04b)
Debt / FCF = 5.19 (Net Debt 7.78b / FCF TTM 1.50b)
Total Stockholder Equity = 16.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.39% (Net Income 2.41b / Total Assets 31.83b)
RoE = 14.89% (Net Income TTM 2.41b / Total Stockholder Equity 16.19b)
RoCE = 15.56% (EBIT 3.70b / Capital Employed (Equity 16.19b + L.T.Debt 7.58b))
RoIC = 11.09% (NOPAT 2.80b / Invested Capital 25.20b)
WACC = 5.35% (E(34.45b)/V(42.91b) * Re(6.38%) + D(8.45b)/V(42.91b) * Rd(1.53%) * (1-Tc(0.24)))
Discount Rate = 6.38% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.00%
[DCF] Terminal Value 84.92% ; FCFF base≈1.60b ; Y1≈1.41b ; Y5≈1.15b
[DCF] Fair Price = 6.07 (EV 34.79b - Net Debt 7.78b = Equity 27.02b / Shares 4.45b; r=5.90% [WACC]; 5y FCF grow -15.03% → 2.90% )
EPS Correlation: 8.23 | EPS CAGR: 104.2% | SUE: -0.01 | # QB: 0
Revenue Correlation: 56.46 | Revenue CAGR: 23.41% | SUE: 1.66 | # QB: 1
EPS current Year (2026-12-31): EPS=0.55 | Chg7d=+0.000 | Chg30d=+0.004 | Revisions Net=+2 | Growth EPS=+7.9% | Growth Revenue=+3.9%
EPS next Year (2027-12-31): EPS=0.60 | Chg7d=+0.000 | Chg30d=+0.005 | Revisions Net=+2 | Growth EPS=+9.2% | Growth Revenue=+5.0%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.6% (Discount Rate 7.9% - Earnings Yield 4.3%)
[Growth] Growth Spread = +1.4% (Analyst 5.0% - Implied 3.6%)